[{"address1": "2625 Townsgate Road", "address2": "Suite 230", "city": "Westlake Village", "state": "CA", "zip": "91361", "country": "United States", "phone": "805 267 9889", "website": "https://www.genelux.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1, an animal health product candidate. It has a licensing agreement with ELIAS Animal Health, LLC. Genelux Corporation was incorporated in 2001 and is headquartered in Westlake Village, California.", "fullTimeEmployees": 22, "companyOfficers": [{"maxAge": 1, "name": "Mr. Thomas  Zindrick J.D.", "age": 64, "title": "Chairman, CEO & President", "yearBorn": 1959, "fiscalYear": 2022, "totalPay": 500000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Sean  Ryder J.D.", "age": 54, "title": "General Counsel & Corporate Secretary", "yearBorn": 1969, "fiscalYear": 2022, "totalPay": 380000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Lourie S. Zak", "age": 60, "title": "CFO & Principal Accounting Officer", "yearBorn": 1963, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Joseph  Cappello Ph.D.", "age": 66, "title": "Chief Technical Officer", "yearBorn": 1957, "fiscalYear": 2022, "totalPay": 213077, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Yong  Yu Ph.D.", "age": 52, "title": "Senior Vice President of Clinical Development", "yearBorn": 1971, "fiscalYear": 2022, "totalPay": 242615, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Prof. Paul  Scigalla M.D., Ph.D.", "age": 77, "title": "Chief Medical Officer", "yearBorn": 1946, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Ralph  Smalling B.Sc.", "age": 66, "title": "VP & Head of Regulatory Affairs", "yearBorn": 1957, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Caroline  Jewett", "age": 58, "title": "VP & Head of Quality", "yearBorn": 1965, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 8, "boardRisk": 6, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 7, "governanceEpochDate": 1709251200, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400, "priceHint": 2, "previousClose": 6.64, "open": 6.72, "dayLow": 6.39, "dayHigh": 6.72, "regularMarketPreviousClose": 6.64, "regularMarketOpen": 6.72, "regularMarketDayLow": 6.39, "regularMarketDayHigh": 6.72, "forwardPE": -7.043956, "volume": 56313, "regularMarketVolume": 56313, "averageVolume": 127823, "averageVolume10days": 175320, "averageDailyVolume10Day": 175320, "bidSize": 800, "askSize": 1000, "marketCap": 171260448, "fiftyTwoWeekLow": 6.29, "fiftyTwoWeekHigh": 40.98, "priceToSalesTrailing12Months": 719.5817, "fiftyDayAverage": 10.5654, "twoHundredDayAverage": 19.551676, "currency": "USD", "enterpriseValue": 143287296, "floatShares": 20179594, "sharesOutstanding": 26717700, "sharesShort": 1223560, "sharesShortPriorMonth": 1081748, "sharesShortPreviousMonthDate": 1705017600, "dateShortInterest": 1707955200, "sharesPercentSharesOut": 0.0458, "heldPercentInsiders": 0.22494, "heldPercentInstitutions": 0.21843, "shortRatio": 9.84, "shortPercentOfFloat": 0.0585, "impliedSharesOutstanding": 26717700, "bookValue": 0.916, "priceToBook": 6.9978166, "lastFiscalYearEnd": 1672444800, "nextFiscalYearEnd": 1703980800, "mostRecentQuarter": 1696032000, "netIncomeToCommon": -25025000, "trailingEps": -1.06, "forwardEps": -0.91, "enterpriseToRevenue": 602.047, "enterpriseToEbitda": -7.268, "52WeekChange": -0.7025089, "SandP52WeekChange": 0.3219322, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "GNLX", "underlyingSymbol": "GNLX", "shortName": "Genelux Corporation", "longName": "Genelux Corporation", "firstTradeDateEpochUtc": 1674743400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "818a2610-5027-31af-b56b-57304f2478db", "messageBoardId": "finmb_11172383", "gmtOffSetMilliseconds": -18000000, "currentPrice": 6.41, "targetHighPrice": 40.0, "targetLowPrice": 30.0, "targetMeanPrice": 33.75, "targetMedianPrice": 32.5, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 4, "totalCash": 29869000, "totalCashPerShare": 1.118, "ebitda": -19716000, "totalDebt": 1896000, "quickRatio": 3.412, "currentRatio": 3.561, "totalRevenue": 238000, "debtToEquity": 7.891, "revenuePerShare": 0.012, "returnOnAssets": -0.62896, "freeCashflow": -14660875, "operatingCashflow": -14883000, "grossMargins": 1.0, "operatingMargins": -85.117645, "financialCurrency": "USD", "trailingPegRatio": null}]